Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J, Distributors May Be Free Of Opioid Litigation If Enough States Sign On To $26bn Settlement

Executive Summary

NY AG has ‘no comment’ on whether criminal charges will be pursued against company executives; NC AG predicts ‘north of 40 states’ expected to accept settlement and would then need to convince municipalities to come on board. States with ongoing litigation against manufacturers may opt for jury trial instead. 

You may also be interested in...



Teva Posts $590m Negative EBITDA Amid Opioid Deal And Write-Offs

Teva’s EBITDA was in the red to the tune of more than half a billion dollars in Q2, after taking a chunk out of the company’s goodwill and adding more than $700m to its loss contingency for opioid-related claims.

Teva Inks $4.35bn Nationwide US Opioids Settlement Agreement

Teva is to put more than $3bn in cash on the table over the next 13 years to resolve longstanding opioid-related claims against the company in the US.

Nationwide Opioid Settlement May Provide Path For Other Manufacturers

J&J and distributors have enough participation from states and subdivisions to move forward with $26bn settlement. The deal, the second largest in US history, may provide a framework for other companies to reach similar agreements. Jury trials remain pending in several states.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS144680

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel